Succinylsulfathiazole

Delayed-Release Tablet Matrices and Intestinal Targeting

Succinylsulfathiazole is incorporated into oral solid dosage forms at unit doses typically ranging from 300 mg to 500 mg per tablet, where the succinyl moiety confers resistance to gastric acid hydrolysis and delays bioavailability until the molecule reaches the ascending colon. During wet granulation, the active pharmaceutical ingredient is blended with microcrystalline cellulose (Avicel PH-102) and a pregelatinized starch binder in a high-shear mixer-granulator operating at impeller speeds of 250–400 rpm and chopper speeds of 1500–2000 rpm. The granulation endpoint is controlled by power consumption monitoring on the main drive, with target moisture content of 2.5–3.5% loss on drying. Tablets are compressed on a rotary tablet press with 10–12 mm round concave tooling to a hardness specification of 8–12 kp (USP <1217>). In vivo, the intact prodrug passes through the stomach and proximal small intestine with minimal systemic absorption; colonic bacterial azoreductases and hydrolases cleave the succinyl group and reduce the azo bond, liberating sulfathiazole locally. A critical process control point is the uniformity of dosage units (USP <905>) because the low aqueous solubility of succinylsulfathiazole (approximately 0.15 mg/mL at 25°C in pH 6.8 phosphate buffer) necessitates particle size reduction to D90 below 30 µm via air-jet milling prior to granulation. Failure to meet this particle size specification results in content non-uniformity and delayed dissolution in simulated intestinal fluid (USP apparatus II, 50 rpm, pH 7.4). The finished product is packaged in HDPE bottles with induction-sealed closures and desiccant canisters to maintain equilibrium moisture below 40% RH, as hydrolytic degradation of the succinyl ester accelerates above this threshold.

What Modulates Release Kinetics in Sulfonamide Combination Therapies?

Fixed-dose combinations pairing succinylsulfathiazole with kaolin, pectin, or streptomycin are granulated in a fluid-bed processor with top-spray configuration, where binder solution viscosity and spray rate directly influence agglomerate porosity and drug release lag time. A typical batch formula contains 30–35 wt% succinylsulfathiazole, 45–50 wt% kaolin light, 10–15 wt% microcrystalline cellulose, and 3–5 wt% crospovidone as disintegrant. The fluid-bed inlet air temperature is maintained at 60–65°C with a product temperature of 32–36°C and spray rate of 15–25 g/min per kilogram of substrate. Excessively rapid spray rates generate overwetted agglomerates that collapse during drying, forming dense granules with low intraparticle porosity and unacceptably prolonged lag phases exceeding 4 hours in USP dissolution testing. The combination is dosified for bacillary dysentery and preoperative bowel antisepsis protocols, where the kaolin component adsorbs bacterial enterotoxins while succinylsulfathiazole reduces colonic microbial load. Dissolution testing per USP <711> employs sequential media: 0.1 N HCl for 2 hours, then pH 6.8 phosphate buffer for the remaining duration, with sampling at 2, 4, 8, and 12 hours. A specification of not less than 75% (Q) dissolved at 12 hours is typical. Granules with bulk density below 0.45 g/cm³ exhibit electrostatic adherence to tablet press feed frames, causing weight variation outside ±5% limits; densification via roller compaction prior to final compression resolves this flow defect. The succinyl ester remains stable during accelerated stability testing at 40°C/75% RH for 6 months only when the combination excludes magnesium stearate above 1.0%, as higher concentrations catalyze transesterification side reactions detectable by HPLC-UV at 254 nm.

Veterinary oral suspensions for poultry and swine operations constitute a high-volume application where succinylsulfathiazole is wet-milled into an aqueous vehicle containing xanthan gum (0.3–0.5% w/v) and sodium benzoate (0.1% w/v) as preservative. The suspension concentrate is prepared at 20–25% w/v active concentration and then diluted into drinking water distribution systems at ratios between 1:1000 and 1:2000 for mass medication during coccidiosis and enteritis outbreaks. Particle size reduction to a D50 of 5–15 µm is achieved through recirculation bead milling with 0.3–0.5 mm yttria-stabilized zirconia grinding media. The mill is operated in a closed-loop configuration with a jacketed grinding chamber cooled to 10–15°C to offset viscous heating. Sedimentation volume ratio (F value) below 0.85 after 24 hours of quiescent storage indicates inadequate suspension stability, requiring reformulation with additional structuring agents. Metering pumps delivering the medicated water must be calibrated to achieve a final drinking water concentration of 0.04–0.1% active, corresponding to a daily intake of approximately 30–50 mg/kg body weight in broiler chickens. Withdrawal periods of 10–14 days prior to slaughter are mandated under FDA 21 CFR §520.2456 to ensure muscle and liver sulfonamide residues fall below 0.1 ppm tolerance. This administration route exploits the same colonic activation mechanism described for human tablets, as the avian gastrointestinal tract provides sufficient residence time in the ceca for bacterial cleavage of the succinyl group.

Granulated Feed Premix Processing and Cross-Contamination Control

Succinylsulfathiazole is dispersed onto a feed-grade calcium carbonate or rice hull carrier at concentrations of 10–25 g active per kilogram of premix for incorporation into complete swine and poultry rations. The blending operation employs a double-ribbon mixer or paddle mixer with a coefficient of variation (CV) for active concentration not exceeding 5% across 10 sampling points within the batch. Premix batches are typically 500–2000 kg, and the active is introduced via a micro-dosing system with accuracy of ±2 g per addition. Following blending, the premix is further diluted into a complete feed matrix at an inclusion rate of 2–5 kg premix per metric ton of finished feed, yielding a final active concentration of 50–125 ppm. Critical-to-quality attributes include the carryover potential during sequential batch production; thorough cleanout of the mixer, bucket elevators, and pellet mill conditioner is required to prevent sulfonamide residues in subsequently manufactured non-medicated feeds. ELISA-based lateral flow strip tests with a limit of detection of 1 ppm sulfathiazole are employed as rapid verification of cleanout efficacy. The pelleting process, where feed mash is conditioned with steam at 75–85°C for 30–60 seconds and extruded through a 3–4 mm die, exposes succinylsulfathiazole to thermal and moisture stress. Stability data indicate that compound recovery after pelleting at 80°C exceeds 95%, but conditioning dwell times beyond 90 seconds initiate measurable hydrolysis, reducing potency by 1–3%. This application is regulated under the Veterinary Feed Directive (FDA 21 CFR Part 558) with specified indications, inclusion rates, and withdrawal times.

Analytical release testing of succinylsulfathiazole as a bulk drug substance verifies that free sulfathiazole content remains below the pharmacopoeial limit, as the unconjugated parent compound would be absorbed in the upper GI tract and contribute to systemic exposure without providing colonic efficacy. The related substances profile is determined using a C18 reversed-phase column with a mobile phase gradient of phosphate buffer (pH 4.5) and acetonitrile, with detection at 254 nm. Principal process impurities include the 4-aminobenzenesulfonamide precursor and the mono-succinyl intermediate. Specifications for residual solvents follow ICH Q3C guidelines, with particular attention to dimethylformamide (Class 2, limit 880 ppm) and acetone (Class 3, limit 5000 ppm) used during the acylation and recrystallization steps of synthesis.

When Topical Sulfonamide Pastes Demand Anhydrous Carriers

Succinylsulfathiazole powder micronized to a particle size below 10 µm (D50) is compounded into anhydrous petrolatum-based ointments at 5–10 wt% loading for wound management in veterinary dermatology, particularly in equine hoof abscesses and bovine foot rot. The anhydrous nature of the base vehicle is critical: the prodrug is hydrophobic and exhibits negligible dissolution in polyethylene glycol or propylene glycol ointments, but even trace water introduced during compounding initiates slow hydrolysis that compromises shelf life. The ointment is prepared by levigation of the micronized powder with a portion of light mineral oil, then geometric dilution into molten white petrolatum maintained at 45–50°C. Final mixing under vacuum in a planetary mixer removes entrapped air, ensuring a smooth semi-solid free from grittiness detectable per USP <785> (osmolality and particulate matter are not applicable; spreadability and film integrity are assessed by rheometry using a 20 mm parallel-plate geometry at 25°C). Release of free sulfathiazole from the ointment film onto an exuding wound surface depends on the slow partitioning of the intact prodrug into the aqueous wound fluid followed by enzymatic hydrolysis by bacterial and endogenous esterases. This dual mechanism provides a sustained topical effect lasting 12–24 hours per application. Incompatibility exists with ointment bases containing zinc oxide: the divalent zinc cation forms an insoluble chelate with the sulfonamide nitrogen of partially hydrolyzed sulfathiazole, precipitating a gritty agglomerate that is visually apparent as white specks and is pharmacologically inactive. 21 CFR §530.41 lists succinylsulfathiazole as approved for extralabel use in food-producing animals under veterinary prescription, with assigned tolerances for edible tissues.

Dusting powders for umbilical cord antisepsis in neonatal livestock represent a niche but historically significant application. Crystalline succinylsulfathiazole is sifted through a 60-mesh (250 µm) screen and blended with sterile talc or kaolin in a 1:3 ratio to yield a free-flowing powder with angle of repose below 35°. The powder is applied directly to the moist umbilical stump, where it adheres and forms a localized zone of bacteriostasis as wound exudate slowly hydrolyzes the prodrug. The absence of caking upon exposure to 75% RH for 24 hours is a critical quality attribute, verified using a controlled-environment chamber. Published data for this specific application configuration is limited; most protocols derive from veterinary practice guidelines issued prior to 1980, and modern alternatives (chlorhexidine-based dips) have largely superseded sulfonamide powders in intensive livestock operations. Nevertheless, the formulation remains relevant in resource-limited settings where cold-chain storage is unavailable and product stability under ambient tropical conditions (30–40°C, 60–90% RH) is required.

Bulk API Pre-Formulation for Regional Repackagers

Succinylsulfathiazole is supplied as a white to off-white crystalline powder in 25 kg fiber drums with double polyethylene liners to pharmaceutical compounding facilities that perform downstream micronization, granulation, and tableting. The bulk density ranges from 0.35 to 0.55 g/cm³ depending on crystallization solvent composition and cooling rate during the final purification step. The material exhibits a melting endotherm at 184–188°C with decomposition (DSC, 10°C/min under nitrogen purge), and this thermal profile precludes hot-melt extrusion as a processing route. Hygroscopicity classification per Ph. Eur. 5.11 indicates the compound is slightly hygroscopic, gaining less than 0.5% mass upon equilibration at 25°C/80% RH for 24 hours. Nonetheless, warehouse storage conditions must be maintained below 25°C and 60% RH, and inventory rotation follows a first-expiry-first-out (FEFO) protocol over a retest period of 36 months. Contract analytical laboratories performing certificate-of-analysis verification must be qualified to ISO/IEC 17025:2017 for pharmacopoeial test methods, including the identification of succinylsulfathiazole by infrared absorption spectrophotometry (USP <197K>) and the limit test for p-aminobenzenesulfonamide (a genotoxic impurity surrogate) by HPLC with derivatization at 450 nm.